Genetics of Congenital Heart Disease: Is the Glass Now Half-Full?

Circulation: Cardiovascular Genetics Pub Date : 2017-06-01 DOI:10.1161/CIRCGENETICS.117.001746

Linda Leatherbury, Charles I Berul

{"title":"Genetics of Congenital Heart Disease: Is the Glass Now Half-Full?","authors":"Linda Leatherbury, Charles I Berul","doi":"10.1161/CIRCGENETICS.117.001746","DOIUrl":null,"url":null,"abstract":"Congenital heart defects are present in 1% of all live births and are a significant burden on the parents and family, healthcare system, and overall community. Congenital heart defects (CHD) are also identified in 10% of still births and are presumed to be a substantial cause of early fetal demise. With advances in prenatal diagnosis, corrective strategies, and longitudinal care, infant mortality has substantially declined. Today >75% of CHD children who survive the first year of live will enter into adulthood. Elucidating the cause of an offspring’s CHD is greatly valued by parents, providing comfort that the defect was because of genetic randomness beyond their control and that certain problems arise from the same underlying genetic issue and not from preventable errors.1 As Helen Taussig stated 50 years ago “Our next great step forward will come in the field of cause and prevention of malformations.”2 Causes of CHD are often divided into genetic and nongenetic influences. The advantage of contemporary genomic technologies including single-nucleotide polymorphism (SNP) arrays, next-generation sequencing, and copy-number variant platforms are accelerating the discovery of genetic causes of CHD. Importantly, these tools enable the study of sporadic cases, the most common presentation of CHD. A review article summarizing this field entitled the “Genetics of Congenital Heart Disease: The Glass Half-Empty” previously highlighted the limitations of genetic technologies for assigning causality.3 Articles such as the present one in this journal entitled “Genome-Wide Association Studies and Meta-analysis for Congenital Heart Defects”4 are important studies performed using distinct patient cohorts from multiple sites. We are now looking for the complex multigenetic explanations for CHD in a multifactorial scheme, including epigenetic and environmental factors. There is renewed optimism in the field such that today we would see the genetics of CHD but hopefully now with the …","PeriodicalId":10277,"journal":{"name":"Circulation: Cardiovascular Genetics","volume":"10 3","pages":"e001746"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1161/CIRCGENETICS.117.001746","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation: Cardiovascular Genetics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1161/CIRCGENETICS.117.001746","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

Congenital heart defects are present in 1% of all live births and are a significant burden on the parents and family, healthcare system, and overall community. Congenital heart defects (CHD) are also identified in 10% of still births and are presumed to be a substantial cause of early fetal demise. With advances in prenatal diagnosis, corrective strategies, and longitudinal care, infant mortality has substantially declined. Today >75% of CHD children who survive the first year of live will enter into adulthood. Elucidating the cause of an offspring’s CHD is greatly valued by parents, providing comfort that the defect was because of genetic randomness beyond their control and that certain problems arise from the same underlying genetic issue and not from preventable errors.1 As Helen Taussig stated 50 years ago “Our next great step forward will come in the field of cause and prevention of malformations.”2 Causes of CHD are often divided into genetic and nongenetic influences. The advantage of contemporary genomic technologies including single-nucleotide polymorphism (SNP) arrays, next-generation sequencing, and copy-number variant platforms are accelerating the discovery of genetic causes of CHD. Importantly, these tools enable the study of sporadic cases, the most common presentation of CHD. A review article summarizing this field entitled the “Genetics of Congenital Heart Disease: The Glass Half-Empty” previously highlighted the limitations of genetic technologies for assigning causality.3 Articles such as the present one in this journal entitled “Genome-Wide Association Studies and Meta-analysis for Congenital Heart Defects”4 are important studies performed using distinct patient cohorts from multiple sites. We are now looking for the complex multigenetic explanations for CHD in a multifactorial scheme, including epigenetic and environmental factors. There is renewed optimism in the field such that today we would see the genetics of CHD but hopefully now with the …

查看原文本刊更多论文

先天性心脏病的遗传学:杯子现在是半满的吗?

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Circulation: Cardiovascular Genetics CARDIAC & CARDIOVASCULAR SYSTEMS-GENETICS & HEREDITY

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Circulation: Genomic and Precision Medicine considers all types of original research articles, including studies conducted in human subjects, laboratory animals, in vitro, and in silico. Articles may include investigations of: clinical genetics as applied to the diagnosis and management of monogenic or oligogenic cardiovascular disorders; the molecular basis of complex cardiovascular disorders, including genome-wide association studies, exome and genome sequencing-based association studies, coding variant association studies, genetic linkage studies, epigenomics, transcriptomics, proteomics, metabolomics, and metagenomics; integration of electronic health record data or patient-generated data with any of the aforementioned approaches, including phenome-wide association studies, or with environmental or lifestyle factors; pharmacogenomics; regulation of gene expression; gene therapy and therapeutic genomic editing; systems biology approaches to the diagnosis and management of cardiovascular disorders; novel methods to perform any of the aforementioned studies; and novel applications of precision medicine. Above all, we seek studies with relevance to human cardiovascular biology and disease.